Pathos AI closes a $237M Series E and signs a neuroscience deal with Bristol Myers
- AI-driven biotech Pathos AI raised a $237 million Series E at a $3 billion valuation.
- Endpoints notes the round came in below the $300 million the company had been associated with.
- The company also signed a neuroscience partnership with Bristol Myers Squibb; terms were not in the feed text.
💡 Points
A $3B valuation on a sub-target raise suggests investors still pay up for AI-biotech, but not at any size. The BMS neuro tie-up matters more as validation: big pharma seems to prefer partnering on difficult CNS biology to buying platforms outright. I'd watch whether the deal carries real milestones or just platform fees.
Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership ↗